FY2024 EPS Estimates for Pyxis Oncology Lowered by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at HC Wainwright reduced their FY2024 EPS estimates for Pyxis Oncology in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($1.00) for the year, down from their prior forecast of ($0.89). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.46) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.44) EPS and FY2028 earnings at ($0.75) EPS.

PYXS has been the subject of a number of other research reports. Stephens initiated coverage on Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price for the company. Stifel Nicolaus assumed coverage on Pyxis Oncology in a research report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Thursday, September 19th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Pyxis Oncology has an average rating of “Buy” and an average target price of $9.57.

Pyxis Oncology Stock Down 2.1 %

NASDAQ PYXS opened at $4.19 on Friday. The company has a 50-day simple moving average of $3.68 and a two-hundred day simple moving average of $3.66. Pyxis Oncology has a 12-month low of $1.35 and a 12-month high of $6.85. The firm has a market cap of $249.16 million, a price-to-earnings ratio of -4.07 and a beta of 1.27.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology during the 1st quarter valued at $59,000. Vanguard Group Inc. increased its stake in shares of Pyxis Oncology by 7.3% during the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock valued at $5,970,000 after purchasing an additional 94,740 shares in the last quarter. StemPoint Capital LP purchased a new position in shares of Pyxis Oncology during the first quarter valued at approximately $7,643,000. Ikarian Capital LLC bought a new stake in shares of Pyxis Oncology in the 1st quarter worth approximately $7,082,000. Finally, Cetera Advisors LLC purchased a new stake in shares of Pyxis Oncology in the 1st quarter worth approximately $100,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.